Do you want to link to this Amgen Site outside the UK and leave

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Limited and Amgen Ireland Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Please specify your location:

Do you want to link to this External Site and leave

YOU ARE NOW LEAVING THIS WEBSITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Collaborative Working initiatives, including Joint Working

At Amgen, we are proud to partner with the NHS and other organisations and are committed to improving patient care through our collaborative working initiatives.

Collaborative working refers to the partnerships formed between pharmaceutical companies and other organisations to deliver initiatives that enhance patient care, are for the benefit of patients, or alternatively benefits the NHS and, as a minimum, maintains patient care. Joint working is a subtype of company collaboration that is specifically patient-centred and designed to always benefit patients.

Full details of our ongoing collaborative working and joint working projects are listed below.

Click here to access the 2021 Amgen UK and Ireland Collaborative Working and Joint Working transfers of value

Click here to access the 2020 Amgen UK and Ireland Collaborative Working and Joint Working transfers of value

Joint Working Initiatives

Title Transforming pathways around lipid management in primary care in Buckinghamshire
Organisations Involved Buckinghamshire CCG and Amgen Limited.
Joint Working Project Description

This Project has been agreed as part of the Accelerated Access Collaborative (AAC).

The AAC was formed in response to the independently chaired Accelerated Access Review published in October 2016. The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to certain products that can transform care.

The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in the health and care system, with full evidence-based recommendations from NICE.

PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products to increase patient access and remove barriers across the health innovation landscape.

Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practices. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve equality of access to these products.

The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake by addressing barriers such as:

  • Lack of patient identification
  • Inconsistent Pathways
  • Limited awareness
  • Restricted prescribing
  • Sporadic LDL-C measurement
  • Treatment complexity

19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for funding from NHS England, Amgen and Sanofi and 6 were selected, including NHS Buckinghamshire CCG.

NHS England have provided equal PTF to the Academic Health and Science Network- North East North Cumbria (AHSN-NENC). AHSN-NENC will distribute this accordingly as agreed by the AAC to the 6 successful sites, one of which being the Partner for this project.

Buckinghamshire CCG and Amgen are working in partnership under a joint working agreement to transform lipid management pathways in primary care by:

  • Creation of Pharmacist-Led Lipid Management Service
  • Development of a clear lipid management pathway for primary care
  • Establishing a “Virtual” Consultant-Led Lipid Clinic
  • Improved Coding

After baselining the current quality of data and coding, a strategy to enhance the frequency and accuracy of coding will be put in place. Outcomes data will be captured and used to refine and optimise the service. This will be critical to support the case for sustainability beyond the pilot.

Expected Outcomes

Predicted benefit to patients:

  • Patients might expect more equitable and consistent care as well as improved and quicker access to care, better education around FH, better access to treatment options, improvement in clinical markers such as lipid levels, a clearer pathway of care with care being delivered closer to home and a better experience of the system. 

Predicted benefit to NHS:

  • Decrease in numbers of patients reviewed with suboptimal lipid control in Bucks
  • Increases in numbers of patients with changes to statin therapy, prescribed adjunctive ezetimibe
  • Increased Patients referred, assessed and potentially initiated on PCSK9i
  • Reduce numbers of patients at risk of secondary CVD

Predicted benefit to Amgen:

  • The project aims to increase the hypercholesterolaemia and mixed dyslipidaemia diagnosis rates. Patients diagnosed with these conditions will be treated with cholesterol lowering medicines which may include an Amgen medicine for suitable patients in line with NICE TA394 and or local / national guidelines.
  • Greater customer understanding
  • Improved reputation through partnering with the AAC initiative

The results of the project will be written up and published to enable the learnings from the project to be shared.

GB-REP-0322-00023 March 2022


Organisations Involved Academic Health Science Network for the North East and North Cumbria (AHSN-NENC) and Amgen Ltd in collaboration with Clinical Commissioning Groups, GP Practices and CDRC (Clinical Digital Resource Collaborative)
Joint Working Project Description

The overall aims of this project are to:

  • Identify patients at high risk of Familial Hypercholesterolemia (FH), evaluate medications, educate and treat patients with the sole aim of reducing excess coronary heart disease risk and premature mortality associated with Familial Hypercholesterolemia (FH).
  • Increase the utilisation of the genetic screening programme across the AHSN footprint through better patient identification.
  • Identify patients at high risk of CVD (>10% 10 year CV risk) and ensure appropriate treatment and management.
  • Improve the patient experience by providing more specialist care within primary care and ensure better utilisation and more appropriate referrals to the specialist service base with the NHS Trust.
  • To continue to refine and develop the FH service model to be adopted both regionally and nationally.
Expected Outcomes

The expected outcomes from this project are as follows:

  • A written document to inform the treatment of Familial Hypercholesterolemia (FH) patients in primary care including information on implementing patient identification using a Familial Hypercholesterolemia (FH) patient identification tool and clinical review at a practice level.
  • A toolkit to include training materials on Familial Hypercholesterolemia (FH) and its treatment for healthcare professionals in primary care and the use of the Familial Hypercholesterolemia (FH) patient identification tool.
  • Implementation of NICE CG71 and the NHS long term plan.

The project incorporates the principles of improved patient education, medicines optimisation and treatment close to home.

GB-REP-0520-00016 May 2020


Title Non-Small Cell Lung Cancer (NSCLC) Tissue Pathway Improvement Project.
Organisations Involved Amgen Limited and Royal Devon & Exeter NHS Foundation Trust on behalf of NHS South West Genomic Medicine Service Alliance
Joint Working Project Description

This collaborative working project seeks to bring together a cross functional team from the Genomics Laboratory Hub (GLH) who in collaboration with Amgen will design and implement a ‘service optimisation project’.

The primary aim of this twelve month project is to support the optimisation of clinical pathways and outcomes, improving and standardising access and turnaround times within the NSCLC Tissue pathway. 

In addition, this project will also inform and support the delivery of improvements in the National Optimal Lung Cancer Pathway. 

Expected Outcomes

The core outputs and outcomes of the of the project are as follows:


  • The delivery of a detailed pathology pathway map for non-small cell lung cancer
  • A detailed report identifying the key barriers and delays within the local non-small cell lung cancer pathology pathway and/or across the local network
  • The development of Optimal Tissue Management guidelines and standard operating policy to support the effective delivery of the non-small cell lung cancer tissue pathway
  • The development of a local ‘case for change’ which supports the continued improvement/ adoption and uptake of genomics testing and informs the local service model
Pathway Outcomes
  • An increased number of lung cancer samples are sent to the GLH vs baseline
  • An improvement in the turnaround time (TAT) from the point of tumour sampling to genomic result v’s baseline
  • An increase and/or standardisation of the quality/type of samples sent for genomic analysis, resulting in the increased success rate of next generation sequencing (NGS) panel and single genome test results
Local system outcomes
  • There is an increased level of education and awareness of local clinical teams, who are better able to engage with the processes supporting genomic analysis of non-small cell lung cancer

GB-NPS-1221-00006 December 2021


Title Predict and Prevent - Transforming the Lipid Pathway in South East London to Improve Patient Outcomes.
Organisations Involved South East London CCG, Guys & St Thomas’ NHS Foundation Trust, King’s College Hospital NHS Foundation Trust.
Joint Working Project Description

This project will assist in the delivery of the CVD ambitions relating to cholesterol outlined by NHS England / PH England in response to the NHS Long-Term Plan.

The primary aim of the project will be to reengineer the local lipid pathway to ensure all patients requiring lipid management are seen by the right person, in the right setting, at the right time to optimise their care. 

The project will focus on the four elements of QIPP - Quality, Innovation, Productivity, Prevention – to transform local lipid pathways across Lambeth and Southwark boroughs to maximise outcomes for patients. 

Expected Outcomes
  • Standardised searches will be developed for GP IT systems to identify high-risk CVD patient cohorts
  • Number of patients identified at practice level within the agreed cohorts
  • Proportion of practices who have undertaken the relevant searches
  • Implementation of revised lipid protocols within participating practices
  • Improvements in lipid control within identified cohorts above, monitored at 6, 12 and 18 months
  • Reduction in absolute numbers of patients requiring lipid intervention when standardised searches are rerun at 6, 12 and 18 months
  • Increased confidence in lipid management across the primary care workforce
  • Clear pathway for referral implemented, including triage process in primary care
  • Increased uptake of second line therapies in line with NICE guidance
  • Integration of new technologies to improve efficiency and patient outcomes
  • Completed evaluation of project submitted for publication
  • Development of business case for sustainability and rollout across SEL CCG
  • Share business case across NHS systems

GB-REP-0720-00002 July 2020




Organisations Involved

The Irish College of General Practitioners (ICGP) and Amgen Ireland Ltd.

Joint Working Project Description

This partnership aims to test the test the feasibility of a general practice-based model of care to increase the detection of FH and high-risk CVD patients in Irish general practice leading to earlier identification and management of their CV risk.

Expected Outcomes

Key Outputs from the Joint Working Agreement include:
  • An increase the number of cases of FH identified through the recording of LDL and family history and a greater proportion of patients receiving management for their LDL-C in a sample of general practices in Ireland.
  • The partnership will generate aggregate data on the prevalence of high-risk CVD including FH in the Irish setting and identify individuals who may benefit from additional management.
  • The data from this partnership will support policy inclusion for a clinical pathway for the diagnosis and management of these patients in General Practice the Irish Healthcare setting.

IE-NPS-2000001 April 2020




Organisations Involved

Amgen Limited and Innovation Agency NWC

Joint Working Project Description

The aim of the Project has been designed to support the delivery of the NHS CVD aspect of the Long-Term Plan.

The focus will be to improve cholesterol management, in Patients who are at a high risk of a CVD event or a further CVD event, to within parameters set by NICE guidelines with a focus on three areas:

  1. Support the clinical priority to reduce the number of CVD events.
  2. Ensure where appropriate, interventions are conducted in primary care by MDT teams within a primary care network (“PCN”) footprint.
  3. Use of population health analysis to identify cohorts of patients who are most in need of an intervention.
Expected Outcomes

Patients with persistently high cholesterol levels who are identified as high Risk for a CVD event or a further CVD event will be reviewed and managed optimally, as per NICE guidance CG181 AND CG71.

Audit tools, treatment and referral pathways as well as Primary Care upskilling to build on current management of Cholesterol will be reviewed with an expected reduction in CVD events as a direct result of optimising cholesterol levels in the practices involved in the project.  

GB-REP-1221-00019 December 2021

Organisations Involved Royal College of Surgeons of Ireland (RCSI), FLS Steering Committee Ireland & Amgen Ireland Ltd
Joint Working Project Description

This partnership with the RCSI aims to establish a Fracture Liaison Service (FLS) database in existing FLS centres.  The FLS Database will collect data that demonstrates to policy makers support for a national FLS in all 16 trauma centres will improve care standards for osteoporosis patients, lead to early identification and treatment initiation to prevent further debilitating fragility fractures.

Expected Outcomes

Key outputs from the Joint Working Agreement include:

  • Demonstrate clinical and cost effectiveness of FLS, by increased identification, investigation & initiation of treatment.
  • Deliver KPI driven quality care improvement
  • Enable prescription initiation & adherence data
  • Development of FLS patient pathway

UKIE-NPC-NPS-1219-080190 December 2019